Christopher Bishop Selected Research

Oxidopamine (6 Hydroxydopamine)

5/2024	The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
7/2023	Moderate intensity aerobic exercise in 6-OHDA-lesioned rats alleviates established motor deficits and reduces neurofilament light and glial fibrillary acidic protein serum levels without increased striatal dopamine or tyrosine hydroxylase protein.
1/2023	Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
1/2021	Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
11/2017	Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
9/2017	D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.
3/2016	Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
1/2016	The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
7/2013	The impact of ventral noradrenergic bundle lesions on increased IL-1 in the PVN and hormonal responses to stress in male sprague dawley rats.
5/2006	Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher Bishop Research Topics

Disease

50	Dyskinesias (Dyskinesia) 05/2024 - 11/2003
48	Parkinson Disease (Parkinson's Disease) 05/2024 - 05/2006
3	Movement Disorders (Movement Disorder) 05/2024 - 12/2013
2	Hypokinesia (Bradykinesia) 07/2023 - 08/2014
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 07/2022
2	Neuroinflammatory Diseases 12/2019 - 01/2019
2	Shock 11/2019 - 07/2013
1	Psychotic Disorders (Schizoaffective Disorder) 01/2023
1	Gliosis 01/2021
1	Diphtheria 01/2021
1	Disease Progression 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 11/2020
1	Neoplasms (Cancer) 11/2020
1	Sleep Wake Disorders 01/2019
1	Inflammation (Inflammations) 04/2016
1	Asthma (Bronchial Asthma) 11/2015
1	Seasonal Allergic Rhinitis (Hay Fever) 11/2015
1	Eczema 11/2015
1	Tremor (Tremors) 08/2014
1	Respiratory Sounds (Crackle) 05/2014

Drug/Important Bio-Agent (IBA)

50	Levodopa (L Dopa)FDA LinkGeneric 05/2024 - 08/2005
33	Dopamine (Intropin)FDA LinkGeneric 05/2024 - 08/2005
10	Oxidopamine (6 Hydroxydopamine)IBA 05/2024 - 05/2006
10	Serotonin (5 Hydroxytryptamine)IBA 07/2022 - 03/2003
9	5-HT1A Serotonin ReceptorIBA 11/2013 - 05/2006
5	SK&F 81297IBA 01/2019 - 12/2008
3	Proteins (Proteins, Gene)FDA Link 02/2024 - 11/2016
3	Vilazodone HydrochlorideIBA 07/2022 - 11/2018
3	Cholinergic Agents (Cholinergics)IBA 01/2021 - 01/2018
3	salicylhydroxamic acid (SHAM)IBA 01/2021 - 06/2011
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2021 - 01/2018
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2020 - 07/2007
3	Glutamic Acid (Glutamate)FDA Link 11/2017 - 06/2011
2	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 07/2023 - 11/2017
2	VortioxetineIBA 01/2023 - 07/2022
2	Dopamine D3 ReceptorsIBA 03/2021 - 01/2021
2	Phosphotransferases (Kinase)IBA 01/2021 - 11/2013
2	gamma-Aminobutyric Acid (GABA)IBA 01/2020 - 01/2016
2	2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)IBA 01/2020 - 01/2017
2	QuinpiroleIBA 01/2019 - 07/2015
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018 - 01/2016
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2018 - 07/2013
2	Immunoglobulin E (IgE)IBA 11/2015 - 05/2014
2	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 09/2009 - 05/2006
2	hydroxide ionIBA 05/2009 - 12/2008
1	alpha-SynucleinIBA 02/2024
1	1- (1- benzyl- 4- hydroxypiperidin- 4- ylmethyl)- 2(1H)- pyridinoneIBA 07/2022
1	Amantadine (Aman)FDA LinkGeneric 01/2022
1	Excitatory Amino Acid AntagonistsIBA 01/2022
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	urotensin IIIBA 01/2021
1	EnzymesIBA 01/2021
1	3,4,4a,10b- tetrahydro- 4- propyl- 2H,5H- (1)benzopyrano(4,3- b)- 1,4- oxazin- 9- olIBA 01/2020
1	Trihexyphenidyl (Artane)FDA LinkGeneric 01/2019
1	AutoreceptorsIBA 01/2019
1	Tropicamide FDA LinkGeneric 01/2019
1	Serotonin ReceptorsIBA 11/2018
1	Glutamate Receptors (Glutamate Receptor)IBA 11/2017
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 11/2017
1	NeurotoxinsIBA 09/2017
1	ropinirole (Requip)FDA LinkGeneric 09/2017
1	AntioxidantsIBA 09/2017
1	3- chloro- 4- fluorophenyl- (4- fluoro- 4- (((5- methyl- 6- methylaminopyridin- 2- ylmethyl)amino)methyl)piperidin- 1- yl)methanoneIBA 01/2017
1	3- chloro- 4- fluorophenyl- (4- fluoro- 4- (((5- methylpyrimidin- 2- ylmethyl)amino)methyl)piperidin- 1- yl)methanoneIBA 01/2017
1	Citalopram FDA LinkGeneric 11/2016
1	nisoxetineIBA 11/2016
1	vanoxerine (I 893)IBA 11/2016
1	Naproxen (Naprosyn)FDA LinkGeneric 04/2016
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 03/2016
1	Clomipramine (Anafranil)FDA LinkGeneric 03/2016
1	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2016
1	AllergensIBA 11/2015
1	Therapeutic UsesIBA 08/2015
1	Clonidine (ST 155)FDA LinkGeneric 08/2015
1	atipamezoleIBA 08/2015
1	beta Adrenergic ReceptorsIBA 07/2015
1	Propranolol (Inderal)FDA LinkGeneric 07/2015
1	Biomarkers (Surrogate Marker)IBA 11/2013
1	Interleukin-1 (Interleukin 1)IBA 07/2013
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2013
1	Dihydrotachysterol (AT 10)IBA 06/2013
1	alpha- (4- fluorophenyl)- 4- (5- fluoro- 2- pyrimidinyl)- 1- piperazine butanolIBA 06/2013
1	Dopamine Agonists (Dopamine Agonist)IBA 06/2013
1	pre-prodynorphinIBA 05/2013
1	Messenger RNA (mRNA)IBA 05/2013
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 05/2013
1	Tuberculin (PPD)IBA 05/2013
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 09/2012
1	Apomorphine FDA Link 09/2012
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 09/2012
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 01/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 06/2011

Therapy/Procedure

19	Therapeutics 01/2023 - 11/2003
3	Drug Therapy (Chemotherapy) 08/2014 - 05/2006
1	Radiotherapy 11/2020
1	Image-Guided Radiotherapy 11/2020
1	Foot Orthoses 11/2019
1	Transcranial Magnetic Stimulation 01/2016
1	Injections 11/2013
1	Denervation 01/2012